Uterine corpus endometrial carcinoma patients were grouped into low‐PHF6 + PHF6 mutation (L + mutation), high‐PHF6 + PHF6 mutation (H + mutation), low‐PHF6 + PHF6 non‐mutation (L + non‐mutation) and high‐PHF6 + PHF6 non‐mutation (H + non‐mutation) for further analysis of overall survival (OS). Here, PHF6 is linked to uterine corpus endometrial carcinoma.